How craving patterns predict success in cannabis addiction treatment

Longitudinal craving profiles in cannabis use disorder: A latent class growth analysis of the achieving cannabis cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) (CTN-0053) trial.

Drug and alcohol dependence • • Moderately Relevant
🤖

AI Summary

This study examines how craving for cannabis changes over time during treatment for cannabis use disorder (CUD), analyzing data from a major clinical trial involving 302 participants. Researchers tracked participants' cravings over 12 weeks of treatment using a standardized assessment scale, identifying four distinct craving patterns: a low craving group (41% of participants), a moderate-decreasing group (38%), a moderate-stable group (11%), and a high craving group (10%). The findings reveal that cannabis craving doesn't follow a single predictable path—instead, people experience vastly different craving trajectories during treatment.

The most critical discovery is that higher craving levels are strongly linked to mental health challenges and treatment failure. Participants experiencing high or moderate-stable craving reported greater baseline anxiety, depression, and obsessive-compulsive symptoms related to cannabis use. Most significantly, the high craving group showed the poorest outcomes, with 96% testing positive for cannabis during the study period, suggesting that intense, persistent cravings are a major barrier to successful cessation. The research suggests that craving intensity and its pattern over time can predict who will struggle most with treatment.

These findings have important practical implications: mental health support may be essential for CUD treatment success, and personalized treatment strategies tailored to individual craving patterns could improve outcomes. The study suggests that healthcare providers should monitor dynamic craving changes rather than viewing craving as a static symptom, potentially identifying patients who need additional interventions before they return to use. This personalized approach could help treatment programs better allocate resources and support to those at highest risk of relapse.

📄 Original Abstract

Craving is a core clinical feature of cannabis use disorder (CUD) and a predictor of treatment outcomes, yet its temporal course during treatment is not well characterized. This study aimed to identify latent classes of cannabis craving trajectories among adults with CUD and examine associated baseline predictors and cannabis use outcomes. This was a secondary analysis of the National Drug Abuse Treatment Clinical Trials Network's CTN-0053 trial, a 12-week, multisite randomized controlled trial of N-acetylcysteine versus placebo for adults with CUD (N = 302). Cannabis craving was measured using the Marijuana Craving Questionnaire-Short Form at six treatment timepoints (weeks 1-5, 9 and 12) and one 5-week post-treatment follow-up (week 17). Urine cannabinoid tests were conducted twice weekly throughout treatment and follow-up. Latent class growth analysis identified craving trajectories. The present study aimed to identify latent classes of cannabis craving over 12 weeks of treatment and examine baseline predictors of class membership. A four-class solution provided the best fit: low craving (41%), moderate-decreasing craving (38%), moderate-stable craving (11%), and high craving (10%). Participants in higher craving classes exhibited greater baseline anxiety, depression, and obsessive-compulsive symptoms related to cannabis use. The high craving class had the greatest proportion of cannabis positive urine tests (96%) and the lowest urine test completion rate. Craving follows heterogeneous trajectories during CUD treatment and is associated with co-occurring mental health symptoms and poorer outcomes. Dynamic craving assessment may support personalized treatment and strategies to prevent return to use.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.